Blog

Plumbing the core and nibbling at the margins of cancer

You, Me, and 23: DTC Gene Tests

Melinda Roberts, Web and Product Development Lead Globiana Inc. Follow Mindy Q: Many people are interested in their own genes and wonder whether they are predisposed to cancer or other maladies.¬† You recently participated in the “23 and me” testing process. As a well-educated and informed consumer, did you find that service useful? Were the […]

Proposed FDA “Conditional Approval”- More Details

Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Follow Al Follow Marty Q: Your April 5, 2017 blog post that proposed a new “Conditional” category for FDA drug approval elicited a number of positive and negative responses. […]

In Memorium: Richard E. Horowitz, M.D.

by Dr. George Lundberg Searching for Truth in Cancer Clinical Trials Richard E. Horowitz, MD, Clinical Professor of Pathology, Keck School of Medicine at USC; Emeritus Professor of Pathology, UCLA School of Medicine; Consulting Pathologist, Los Angeles Veteran’s Affairs Medical Center Q: Who has been among the strongest supporters and most constructive critics of CollabRx […]

Fibrolamellar Hepatocellular Carcinoma: Still Rare but Deadly

John R. Craig, MD PhD, Retired pathologist and formerly Medical Director, St. Jude Cancer Center, Fullerton, CA; Member, Board of Directors, FibroFoundation Q: You were the lead author in a 1980 paper in Cancer that clearly delineated an unusual form of Hepatocellular Carcinoma that you termed “Fibrolamellar Carcinoma”. Now, 37 years later, what insights of […]

A Proposed New FDA Drug Approval Pathway: “Conditional”

Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Follow Al Follow Marty Q: The delay time from discovery/observation, through validation to approval and distribution/use of new cancer treatments remains excessive. With promising experimental treatments, advanced computer technology […]

AACR: Advances in Immunotherapy to Continue

Srivani Ravoori, PhD, Associate Director, Science Communications; American Association for Cancer Research Intro: The American Association for Cancer Research (AACR) publishes a forecast blog post at the start of each year to ask¬†prominent cancer research leaders what they envision the new developments will be in areas like immunotherapy, precision medicine, cancer prevention, and health disparities. […]

A Fully Integrated Histo-Molecular Pathology Report

Margaret L. Gulley, MD, Professor of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill Q: The CAP, ASCO, ASCP and AMP have developed guidelines for interpretation and reporting of NGS variants in cancers. These analyses are performed in a wide range of types of labs and involve professionals from many disciplines. The […]

Paying for Precision Oncology – Who Decides?

Patricia Deverka, Principal Researcher, Health Care Group American Institutes for Research, Chapel Hill, NC; Adjunct Associate Professor, Center for Pharmacogenomics & Individualized Therapy, University of North Carolina at Chapel Hill Q: Paying for Precision Oncology – Who Decides? A: There is tremendous enthusiasm for the scientific rationale and clinical promise of precision oncology amongst researchers, […]

A Plea for Gold Standards in Precision Oncology

George Lundberg, MS, MD, ScD, MASCP, FCAP, Chief Medical Officer and Editor in Chief, CollabRx, a Rennova Health Company; Editor at Large, Medscape; Executive Adviser, Cureus; Consulting Professor of Pathology and Health Research and Policy, Stanford University; President and Chair, The Lundberg Institute; @glundberg Q: Is Precision Oncology Accurate? A: Precision oncology in 2017 is […]

Precision Oncology: Requirements for the Next Leap Forward

Razelle Kurzrock, MD, Chief, Division of Hematology and Oncology, UCSD School of Medicine; Senior Deputy Director, Clinical Science; Director, Center for Personalized Cancer Therapy; Director, Clinical Trials Office, UCSD Moores Cancer Center, San Diego, California Q: Some workers in the field of precision oncology are growing despondent because of observed limitations of therapeutic effectiveness. What […]